Travere Therapeutics (TVTX.US) Price Target 2026/2027: 50% Upside – Rating and Stock Analysis

48.30
Price history for Travere Therapeutics (TVTX.US) – stock price at $48.30, November 2026
Travere Therapeutics stock price – price development 2026. Updated Nov 20, 2026.
Share this analysis:

Travere Therapeutics Price Target 2026: Analysts See 52% Upside

The average price target for Travere Therapeutics is $73.43. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 52.03% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.
⚠️ Don’t buy a stock just because of its price targetA price target is the analysts’ estimate of where the stock will trade in 12 months. That estimate is often wrong. A large study of US stocks from 2000 to 2009 found that only 38% of price targets had been met after 12 months. On average, the targets promised 15 percentage points more return than the stocks delivered. Use the price target together with the financials and the trend, not on its own.Source: Bradshaw, Brown and Huang (2013)

Is Travere Therapeutics overvalued or undervalued?

Travere Therapeutics is currently undervalued with a gap of 52% relative to the price target.


The current price is $48.30, which places Travere Therapeutics in the undervalued category. The stock is considered undervalued when the price is below $66.09, and overvalued when the price exceeds $80.77.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Travere Therapeutics, the fair value range lies between $66.09 and $80.77.


See the full price target analysis for Travere Therapeutics →

Analyst Ratings for Travere Therapeutics stock in 2026: Strong Buy

15 analysts cover Travere Therapeutics. There is broad agreement on a positive view — 93.3% recommend buying. The average price target is $73.43, which gives an upside of 52% from the current price.

Consensus: Strong Buy (4.73/5)
Strong Buy
12 (80%)
Buy
2 (13.3%)
Hold
1 (6.7%)
Strong Sell Sell Hold Buy Strong Buy
4.73 out of 5 based on 15 analysts

About Travere Therapeutics – Biotechnology

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California. Read more about the company

Key Figures for Travere Therapeutics

$4.8B Market cap
$651M Revenue
Biotechnology Industry
- P/E
7.33 P/S
215.24 P/B
United States Listed on exchange

What kind of stock is Travere Therapeutics?

Speculative stock

Travere Therapeutics is classified as a speculative stock.

Score Overview for Travere Therapeutics

💰 Value Score 5/100 (Very Low)
⭐ Quality Score 18/100 (Very Low)
🚀 Momentum Score 45/100 (Neutral)
📊 Total Score 22/100

⚠️ 6 red flags identified 3 critical

Our analysis has identified 6 potential risk factors in Travere Therapeutics that investors should be aware of.

🚨 High debt: The debt-to-equity ratio is 906% – the company carries considerably more debt than equity, which raises the financial risk.
⚠️ Weak financial health: The Piotroski score is only 3/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Weak balance sheet (elevated risk): Altman Z2 is -4.04 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
⚠️ Negative profit margin: The profit margin is -18.7% – the company is losing money on its operations.
🚨 Negative return on equity: ROE is -321.2% – the company is generating a negative return for shareholders.
⚠️ High short interest: 12.9% of the shares are sold short – many professional investors are betting on price declines.

📈 Valuation

The P/S ratio is 7.3 (high — the market pays a premium for the revenue). The P/B ratio is 215.2.

🏦 Financial Health

The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is -4.04 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 905.7% — high debt, which raises the risk.

🚀 Momentum & Short Interest

Short interest is 12.90% — very high, the market is skeptical.

Insider Trading in Travere Therapeutics 2026: Only sells

In 2026, insiders at Travere Therapeutics have made 20 transactions, all of which were sales. On a net basis, insiders took $80,996,763 out of the stock. Active insiders include Dube Eric M, Heerma Peter, ROTE WILLIAM E. and others. Over the last 3 months: only sells.

Last 3 Months: Only sells

Insiders have exclusively sold shares over the last 3 months.

Over the last 3 months: 0 purchases and 15 sales. A net $79,496,871 out of the stock.

All Transactions: Only sells

Insiders have exclusively sold shares in the recent period. This can suggest management sees limited opportunity.

Across the last 20 transactions: 0 purchases and 20 sales. A net $80,996,763 out of the stock.

Latest sale: Dube Eric M sold 243,735 shares at $53.82 each on 2026-10-15.

Who is selling: Dube Eric M, Heerma Peter, ROTE WILLIAM E., REED ELIZABETH E, Inrig Jula and others.

Latest Insider Trades in Travere Therapeutics (2026)

The table shows the last 20 reported insider transactions in Travere Therapeutics. Green rows are purchases, red rows are sales. The data is based on official filings.

Transaction date Name Type Number of shares Price per share (USD) Total amount (USD)
2026-10-15 Dube Eric M Sell 243,735 53.82 13,117,818
2026-09-17 Heerma Peter Sell 8,282 65.07 538,910
2026-09-17 Dube Eric M Sell 108,493 64.61 7,009,733
2026-09-16 ROTE WILLIAM E. Sell 112,850 63.33 7,146,791
2026-09-16 Heerma Peter Sell 172,717 63.43 10,955,439
2026-09-16 Dube Eric M Sell 195,841 63.45 12,426,111
2026-09-15 ROTE WILLIAM E. Sell 96,198 62.25 5,988,326
2026-09-15 REED ELIZABETH E Sell 37,500 62.34 2,337,750
2026-09-15 Inrig Jula Sell 44,674 62.34 2,784,977
2026-09-15 Heerma Peter Sell 102,190 62.26 6,362,349

Who is buying and selling Travere Therapeutics shares in 2026?

The following insiders have sold shares: Dube Eric M, Heerma Peter, ROTE WILLIAM E., REED ELIZABETH E, Inrig Jula and others. In total, $80,996,763 was sold across 20 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.

Travere Therapeutics Short Selling 2026: 12.9% Sold Short

Very high short interest: 12.9% of the free float
Short % of free float
12.9%
Assessment
Very high short interest
Short squeeze risk
High
Data source
EODHD
Reported about twice a month
The stock has a very high share of short selling. Between 10-20% of the freely traded shares are sold short, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains.

What does this mean for you as an investor?
A short interest of 12.9% means that 12.9% of the freely traded shares in Travere Therapeutics have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
12.9%

When Does Travere Therapeutics Report Earnings?

The next earnings date for Travere Therapeutics is not yet available. Check the company's investor calendar for more information.



Technical Analysis of Travere Therapeutics 2026 – Signal: Hold

Overall Technical Signal: Hold

Based on whether the price is above or below its 50-day and 200-day averages, and whether MACD is positive or negative (daily + weekly). Updated November 20, 2026.

Technical analysis of Travere Therapeutics (TVTX.US) – RSI 38, MACD negative (bearish), daily candlestick chart November 2026
Travere Therapeutics technical analysis – candlestick chart with RSI, MACD and volume profile. Updated Nov 20, 2026.

Trend Analysis of Travere Therapeutics, Inc

The price of $48.30 is 4.3% below the 20-day average ($50.48). Medium term, the picture is negative: the price is 11.6% below the 50-day average ($54.62). Long term, the stock is 0.5% above the 200-day average ($48.04).

Overall trend: Sideways. Uptrend: the price is above its 50-day average, and the 50-day is above the 200-day. Downtrend: both below. Otherwise sideways.

Golden Cross: The 50-day average (54.62) is above the 200-day average (48.04), which is a classic bullish signal for Travere Therapeutics, Inc.

Is Travere Therapeutics, Inc overbought or oversold?

Travere Therapeutics, Inc has an RSI of 38.4. That is the lower part of the neutral zone (30-70). The stock is at the same time moving sideways.

MACD Analysis for Travere Therapeutics, Inc

Daily MACD: MACD is negative (-1.125) – the 12-day EMA is below the 26-day EMA – and lies above the signal line (-1.274) by 0.149.

Weekly MACD: The weekly MACD is positive (1.374) and lies below its signal line (3.887) by 2.513.

Risk Profile for Travere Therapeutics, Inc

Travere Therapeutics, Inc has an annual standard deviation of 62.3%, which classifies the stock as Speculative. Sizeable price swings are normal, and the stock requires a higher risk tolerance.

Overall Technical Conclusion for Travere Therapeutics, Inc

Trend: Sideways. The price and the two averages do not point the same way.

MACD trend (zero line): Daily bearish (-1.125). Weekly bullish (1.374).

MACD momentum (signal): Daily rising. Weekly falling.

RSI: 38.4 – neutral.

Technical signal: Hold

The technical signal counts 4 measurements: whether the price is above its 50-day and 200-day average, and whether MACD is positive daily and weekly. Here 2 of 4 are positive. It describes the price now and is not advice to buy or sell.

Who Owns Travere Therapeutics?

The three largest owners of Travere Therapeutics are Jupiter Topco LLC (11.8%), BlackRock Inc (8.4%) and FMR Inc (7.4%). The percentage is their share of the stock, as of Jun 30, 2026. Source: our data provider EODHD.

The 10 Largest Institutions

InstitutionStakeChange
Jupiter Topco LLC11.80%0.0%
BlackRock Inc8.36%+2.9%
FMR Inc7.39%−35.3%
Bank of America Corp4.76%+239.6%
State Street Corp4.43%−14.2%
Vanguard Capital Management, LLC4.28%+1.6%
Perceptive Advisors LLC3.91%−9.4%
Delaware Management Holdings Inc2.93%−14.0%
Adage Capital Partners Gp LLC2.68%+163.0%
Geode Capital Management, LLC2.47%+0.1%

As of Jun 30, 2026. "Change" is the change in shares held since the holder's previous report.

The 5 Largest Funds

FundStakeChange
Vanguard MStar Total Stk Mkt Idx Invest3.09%+0.3%
State Street® SPDR® S&P® Biotech ETF2.49%+2.7%
iShares Russell 2000 ETF2.36%0.0%
Nomura Small Cap Core I1.54%−5.6%
Vanguard Explorer Inv1.50%+5.7%

As of Oct 30, 2026. A fund may be managed by one of the institutions above, so the two lists cannot be added together.

Frequently Asked Questions About Travere Therapeutics stock in 2026

Should you buy Travere Therapeutics stock now?
The technical signal for Travere Therapeutics is currently Hold. Travere Therapeutics trades at $48.30 as of Nov 20, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -1.125 with rising momentum (signal: -1.274); RSI is at 38.4 (neutral zone); the price is below the 20-day average; the analyst price target of $73.43 points to 52.0% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Travere Therapeutics stock?
The average analyst price target for Travere Therapeutics is $73.43. The current price is $48.30, which gives an upside of 52.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $66.09 and $80.77.
Is Travere Therapeutics a dividend stock?
No, Travere Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Travere Therapeutics stock?
Travere Therapeutics is rated as a stock in the risk category Speculative. the annual standard deviation is 62.3%, which classifies the stock as Speculative.
Is Travere Therapeutics overvalued?
No, Travere Therapeutics is considered undervalued based on the analyst price target (52.0% upside). Travere Therapeutics has the following valuation ratios: a P/S ratio of 7.3, a P/B ratio of 215.2. The analyst price target suggests that the stock is undervalued by 52.0%.
Is Travere Therapeutics overbought?
No, Travere Therapeutics is not overbought. RSI is at 38.4 (neutral zone). The technical indicators show: RSI is at 38.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.3% below the 20-day average. In addition, MACD is negative, but momentum is rising. The stock is at the same time moving sideways.
When is the next Travere Therapeutics earnings report?
The date of the next earnings report for Travere Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Travere Therapeutics shorted?
Yes, Travere Therapeutics is shorted with 12.9% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Travere Therapeutics stock?
No, insiders are not buying Travere Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 15 sales. On a net basis, 79,496,871 USD worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 80,996,763 USD sold. Active sellers include Dube Eric M, Heerma Peter, ROTE WILLIAM E. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Travere Therapeutics a good stock?
Based on our total score, Travere Therapeutics is rated as a poor stock with a total score of 22 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 5/100, Quality: 18/100, Momentum: 45/100. In addition: analysts see 52.0% upside to the price target. Whether now is the time to buy is a separate question: the technical signal is Hold. Whether Travere Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Travere Therapeutics stock?
The outlook for Travere Therapeutics based on current data: the average analyst price target is $73.43 (+52.0%). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Travere Therapeutics stock falling?
Travere Therapeutics is falling right now. The technical indicators show: the price is 4.3% below the 20-day average; short interest is 12.9% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Travere Therapeutics go?
The average analyst price target for Travere Therapeutics is $73.43, which corresponds to a potential gain of 52.0% from the current price of $48.30. The stock has traded between $22.59 and $68.73 over the last 52 weeks. The price is 29.7% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Travere Therapeutics fall?
The stock has traded as low as $22.59 over the last 52 weeks — that is 53.2% below the current price of $48.30. The biggest decline (drawdown) in the same period was 67.1% from high to low. Within a year, the price typically swings about ±62.3% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash.
What does Travere Therapeutics do?
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to ... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Travere Therapeutics as an investment.
Did Travere Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Travere Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Travere Therapeutics making money or losing money?
No, Travere Therapeutics is currently not making money — the company is losing money with a negative profit margin of -18.7%, a noticeable loss. That means the business loses money on every dollar of revenue. The operating margin (profit before interest and taxes) is also negative at -3.1% — so it is not just financing costs weighing on the result. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Travere Therapeutics go bankrupt?
The bankruptcy risk of Travere Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -4.04 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 906% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Travere Therapeutics have a lot of debt?
Yes, Travere Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 906%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Travere Therapeutics service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -30.3x, and net debt equals 15.2 years of earnings (EBITDA).

Other Stocks in Healthcare

Compare Travere Therapeutics with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 127 stocks in the Healthcare sector